CCA
STOK icon

Catalyst Capital Advisors’s Stoke Therapeutics STOK Stock Holding History

Catalyst Capital Advisors’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-240
Closed -$7K – 476
2019
Q2 		$7K Buy
+240
New +$6.45K ﹤0.01% 354

Other funds holding STOK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Catalyst Capital Advisors's STOK Position: Q3 2019 in Review

Catalyst Capital Advisors sold out of Stoke Therapeutics (STOK) in Q3 2019, closing a stake of 240 shares — an estimated $7K sold.

Catalyst Capital Advisors first reported a position in STOK in Q2 2019 and held it in 1 quarter. The position peaked at $7K in Q2 2019. 53 funds tracked by Wall St. Rank hold STOK as of Q3 2019.

  • Catalyst Capital Advisors reported no remaining Stoke Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Catalyst Capital Advisors sold 240 Stoke Therapeutics shares in Q3 2019, an estimated $7K.
  • Catalyst Capital Advisors first reported a position in Stoke Therapeutics in Q2 2019 and held it in 1 quarter.
  • Catalyst Capital Advisors's Stoke Therapeutics position peaked at $7K in Q2 2019.
  • 53 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q3 2019.

Based on Catalyst Capital Advisors's 13F filing for Q3 2019, filed 5 Nov 2019.